Urogen Pharma (URGN)
NASDAQ:URGN
Want to see URGN full AI Analyst Report?
URGN Stock Chart & Stats
$22.54
-$0.02(-0.18%)
At close: 4:00 PM EST
$22.54
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$3.42 - $30.00
Previous CloseN/A
Volume157.75K
Average Volume (3M)682.65K
Market Cap
$1.18B
Enterprise Value$1.20B
Total Cash (Recent Filing)$120.46M
Total Debt (Recent Filing)$128.33M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
May 07, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding48,682,280
10 Day Avg. Volume770,905
30 Day Avg. Volume682,655
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue10.94
Enterprise Value/Gross Profit12.34
Enterprise Value/Ebitda-8.85
Forecast
1Y Price Target
$37.40Price Target Upside65.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.14
Revenue Forecast (FY)$243.11M
Bulls Say, Bears Say
Bulls Say
Commercial Momentum And Physician AdoptionAnalyst reports accelerating launch metrics, including rising activated treatment sites, doubled unique prescriber counts, and shorter treatment initiation times, which support sustained sales growth as uptake builds.
Regulatory Approval And Market PositioningAnalyst highlights Zusduri's status as the first FDA-approved non-surgical treatment for recurrent intermediate-risk non-muscle invasive bladder cancer, giving it a first-mover advantage and broader patient eligibility versus biomarker-restricted competitors.
Reimbursement ClarityAnalyst notes permanent J-code activation for Zusduri should simplify reimbursement, reduce billing friction for providers, and broaden patient access by making claims processing more routine.
Bears Say
Operational Bottlenecks Affecting RevenueAnalyst indicates operational hurdles such as long times to treatment initiation and delayed claims remittance can compress near-term revenue recognition and slow cash collection.
Profitability ConcernsAnalyst points out the company reported a net loss for the most recent fiscal year, signaling ongoing profitability challenges that could pressure the stock until margins improve.
Reimbursement And Buy-and-bill BarriersAnalyst cautions that complex reimbursement processes and buy-and-bill economics continue to constrain adoption, creating headwinds for therapy uptake until provider billing workflows are widely resolved.
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $3.42 and its highest was $30.00 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.18B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is May 07, 2026 which is in 13 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Mar 02, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.502 by -$0.038.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.48.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,682,280 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.502. Following the earnings report the stock price went down -12.35%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.40 (65.93% Upside)
$37.40 (65.93% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 238.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $145.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
133.09%
12-Months-Change
Fundamentals
Return on Equity
170.21%
Trailing 12-Months
Asset Growth
-29.84%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
URGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful positive commercial and clinical momentum: a material ramp in revenue driven by Jelmyto and the Zasturi launch (21% total revenue growth in 2025), clear evidence of early adoption acceleration following a permanent J‑code, robust Phase 3 data for next‑generation programs (UGN‑103) with a defined regulatory path, and a refinancing that strengthens liquidity and extends runway. Offsetting these positives are a widening net loss, higher R&D and projected operating expenses in 2026, and continued uncertainty because no formal 2026 sales guidance for Zasturi was provided. On balance, the highlights — especially commercial acceleration, clinical success and improved balance sheet — outweigh the lowlights, but execution in 2026 will be critical to translate early momentum into durable financial improvement.View all URGN earnings summariesURGN Stock 12 Month Forecast
Average Price Target
$37.40
▲(65.93% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
1.95% Insiders
5.85% Mutual Funds
0.06% Other Institutional Investors
85.12% Public Companies and
Individual Investors